Calixar

Executive Summary

Calixar is a French biotechnology company specializing in the production of custom, functional, and stable proteins, with a particular expertise in membrane proteins. Founded in 2011 and headquartered in Lyon, the company offers end-to-end services from protein construct design to large-scale production, primarily serving drug discovery and development programs. Its proprietary technology focuses on generating fully native, wild-type, and unaltered protein targets, which is critical for accelerating research in antibody development, structural biology, and vaccine discovery. By providing high-quality membrane proteins that retain their native conformation, Calixar enables more accurate drug screening and improves the success rate of therapeutic programs targeting G protein-coupled receptors, ion channels, and transporters. Despite being a private company with limited publicly available financial data, Calixar has established itself as a key enabler in the biopharma ecosystem, particularly for clients seeking to develop antibodies or small molecules against difficult-to-express membrane proteins. The company's service model mitigates the high failure rates associated with membrane protein research, a major bottleneck in drug discovery. As the demand for biologics and targeted therapies grows, Calixar is well-positioned to benefit from increased outsourcing of specialized protein production. However, its growth may depend on expanding its client base and securing strategic partnerships with large pharmaceutical companies.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a top-20 pharmaceutical company for membrane protein production40% success
• Q4 2026Expansion of production capacity or new facility to meet growing demand30% success
• Q2 2026Publication of a peer-reviewed study showcasing a novel membrane protein platform50% success